UNSPSC 51171635: Bisoxatin

This classification denotes an oxazine with the molecular formula C20H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C75N0L7FP, chemically known as 2,2-bis(p-hydroxyphenyl)-3-oxo-dihydrobenzoxazin-(1,4) but generally known as bisoxatin, which bears US NIH Compound Identifier 28689. bisoxatin most often comes in base and acetate forms. European Medicines Agency schedules Bisoxatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05856MIG.

UNSPSC 51171635 Bisoxatin, a Commodity code, covers pharmaceutical products but state and local procurement activity under this code shows minimal recent direct application — the three most recent opportunities tagged to it span offender drug testing services, therapeutic pharmacy initiative market research, and a multistate cooperative pharmaceutical supply agreement, none of which involve bisoxatin as a named or specified product. Bisoxatin is a stimulant laxative used in pharmaceutical formulations; the code nominally represents individual active pharmaceutical ingredients or bulk chemical compounds. State and local issuing bodies soliciting under related pharmaceutical codes typically include state health and human services departments, corrections departments, multistate cooperative purchasing organizations, and county community supervision agencies. The work being procured ranges from bulk pharmaceutical ingredients for formulary inclusion to finished-goods pharmaceutical supply agreements serving institutional and clinical settings across multiple jurisdictions.

Recent activity shows Texas agencies and multistate cooperatives as active buyers. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services (response due July 23, 2026, estimated contract value $600,000), which involves pharmaceutical testing methodologies but does not specify bisoxatin procurement. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs — an exploratory market intelligence effort rather than a binding solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. The geographic spread reflects Texas and upper-midwest activity, with MMCAP representing a multi-state cooperative vehicle. Direct opportunities for bisoxatin as a specified commodity appear limited in recent postings; pharmaceutical supply agreements and formulation contracts at the state and local level typically address broader product classes rather than individual active ingredients unless part of a specialized therapeutic initiative or bulk chemical procurement.